Vitiligo Treatment by Targeting TYK2 Mediated Responses

NCT06327321 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

128

Enrollment

OTHER

Sponsor class

Conditions

Vitiligo, Generalized

Interventions

DRUG: Deucravacitinib
OTHER: Volunteer without treatment

Sponsor

Centre Hospitalier Universitaire de Nice